Aidoc, a well-funded radiology AI company, on Wednesday announced it received FDA clearance for a a tool that can triage 14 critical findings in a single abdominal CT scan: liver injury, spleen injury, bowel obstruction, appendicitis, and more.
As my colleague Katie Palmer reports, the new AI hints at a coming future. More developers are experimenting with large vision models that can be used to identify many different conditions from a single x-ray, MRI, or CT scan. This may require new regulatory approaches from FDA which right now evaluates indications one at a time.
While creating a single product that can scan for many conditions may simplify workflows for radiologists who must juggle a growing arsenal of technology at their disposal, it could also amplify risks, including that an AI will falsely identify signs of a condition a patient doesn’t have.
Read more here
Cancer
Benefit from Moderna’s skin cancer immunotherapy endures
From STAT’s Matthew Herper: Moderna and Merck said that adding the cancer immunotherapy intismeran autogene to Keytruda slowed the rate of relapse or death in patients with metastatic melanoma by 51% after five years.
That is exactly the benefit that was seen in an analysis of the treatment, an mRNA therapy that primes patients’ immune systems to attack tumors, at three years in the same 157-patient clinical trial. The original results of the study were published in the Lancet in 2024. Volunteers were given either the new therapy and Keytruda alone after surgery to remove their cancer.
The durable benefit relative to Keytruda indicates that patients are continuing to benefit. Moderna did not respond to requests to clarify the absolute rate at which patients on the therapy are going without disease recurrence or death. Merck and Moderna have fully enrolled a Phase 3 study of the treatment in melanoma and are enrolling separate Phase 3 studies in lung cancer.
from AXIOS:
| Vaccine changes pit docs against feds | ||||
| By Caitlin Owens | ||||
![]() |
||||
| Illustration: Aïda Amer/Axios | ||||
| Parents around the country are suddenly confronting a bizarre dynamic: Their pediatrician’s vaccine advice doesn’t match that of the federal government.
Why it matters: Kids’ health is at stake at a time when vaccine-preventable diseases are on the rise and trust in public health institutions is already low. State of play: Doctors and health systems are ignoring the Trump administration’s new and narrower childhood vaccine recommendations and sticking to the old schedule.
What they’re saying: “This is the first time in memory that parents aren’t able to count on federal health agencies to provide evidence-based vaccine recommendations,” said Michael Osterholm, director of the the Center for Infectious Disease Research and Policy and the Vaccine Integrity Project. Between the lines: The Trump administration has stressed that all of the previously recommended vaccines will still be covered by insurance, and that whoever wants them will be able to get them.
Keep reading |
||||
| Congress pushes back against Trump’s NIH cuts | ||||
| By Peter Sullivan | ||||
![]() |
||||
| Illustration: Allie Carl/Axios | ||||
| Republicans and Democrats are using the latest government funding package to push back against President Trump’s proposed cuts to NIH — and limit the administration’s influence over biomedical research grants.
Why it matters: The bipartisan sentiment shows that efforts to find new cures still have strong support on Capitol Hill after a turbulent year for the agency. Driving the news: The health care portion of the spending package released early Tuesday includes $48.7 billion for NIH — an increase of $415 million, and a far cry from the roughly 40% cut in President Trump’s budget request.
Yes, but: NIH grant cancellations, program cuts and other unilateral moves by the administration are unlikely to stop. Read more from AXIOS:
|


